Navigation Links
Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:3/1/2012

SAN DIEGO, March 1, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference at noon EST on Wednesday, March 7, 2012, at the Boston Marriott Copley Place in Boston, Massachusetts. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its clinical development programs.

"This is an exciting time at Receptos as we move forward with plans to initiate multiple Phase 2 clinical trials later this year and to close our Series B financing round," Hasnain said. "This presentation at the Cowen and Company Health Care Conference gives us the opportunity to provide an update about these initiatives, as well as other areas of focus for Receptos."

About RPC1063 and S1P1 Agonists
RPC1063, developed in the labs of Receptos, is a novel, highly selective S1P1 agonist exhibiting picomolar potency that is effective in rodent models of multiple sclerosis, and possesses an excellent safety profile in non-clinical toxicology studies. In addition to selectivity, which reduces the likelihood of "off-target" side effects, RPC1063 has an appropriately short half-life to promote rapid reversibility of lymphopenia. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In the disease state of multiple sclerosis, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying autoimmune cause of multiple sclerosis.

About Receptos
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information‐driven drug discovery, including GPCR structure determination. The company's lead program is a best‐in‐class S1P1 small molecule agonist candidate for autoimmune indications, including multiple sclerosis and inflammatory bowel disease, which will complete a Phase 1 clinical study in the first quarter of 2012. The S1P1 program is supported by the company's proprietary high resolution protein crystal structure of the S1P1 receptor. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit www.receptos.com.

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271
Ian.stone@russopartnersllc.com
David.schull@russopartnersllc.com

Cindy McGee (investors)
(619) 308-6538
Cindy.mcgee@russopartnersllc.com


'/>"/>
SOURCE Receptos Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science
2. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
3. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
5. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
6. Regeneron Announces March 2012 Investor Conference Presentations
7. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
8. OncoSec to Present at 10th Annual BioPartnering North America
9. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
10. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
11. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
Breaking Biology News(10 mins):